Nivolumab is a type of immunotherapy drug that is used to treat several types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma. According to the drug's prescribing information, nivolumab is typically administered intravenously over 30 minutes every 2 weeks (or every 3 weeks for certain types of cancer) until disease progression or unacceptable toxicity occurs.

The National Comprehensive Cancer Network (NCCN) guidelines recommend nivolumab as a single agent or in combination with other drugs for the treatment of several types of cancer. The NCCN guidelines suggest that nivolumab should be administered at a dose of 240 mg every 2 weeks or 480 mg every 4 weeks.

It is important to note that the dosage and frequency of nivolumab administration may vary depending on the patient's condition, the type of cancer being treated, and other factors. Healthcare providers will determine the appropriate dosage and schedule for each patient based on their individual needs.

In summary, nivolumab is typically administered intravenously every 2 weeks or every 3 weeks, depending on the type of cancer being treated. The dosage may vary, but the typical dose is 240 mg every 2 weeks or 480 mg every 4 weeks.

Sources:

1. [Nivolumab prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125554s000lbl.pdf)
2. [National Comprehensive Cancer Network (NCCN) guidelines](https://www.nccn.org/professionals/physician_gls/pdf/nivolumab.pdf)
3. [DrugPatentWatch.com](https://www.drugpatentwatch.com/drugs/nivolumab)